MarketCap
Facebook
X
Telegram
AbbVie DPO Ratio | ABBV
Annual DPO Ratio AbbVie
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 65.5 | 71.6 | 59.2 | 61 | 54 | 44.2 | 71.2 | 73.1 | 76.4 | 88 | 130 | 72.7 | 74.3 | 45 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 130 | 44.2 | 70.4 |
Quarterly DPO Ratio AbbVie
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 38.9 | 36 | - | - | 33.6 | 30.6 | - | - | 41.1 | 29.5 | - | - | 33.6 | 32.1 | - | - | 32.5 | 30.4 | - | - | 24.6 | 22.2 | - | - | 34.1 | 33 | - | - | 41.6 | 34.9 | - | - | 34.9 | 29.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 41.6 | 22.2 | 32.9 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Brickell Biotech
BBI
|
105 | - | -5.38 % | $ 6.06 M |  USA |
 |
Clearside Biomedical
CLSD
|
4.48 K | - | - | $ 25.3 M | USA |
 |
22nd Century Group
XXII
|
60.9 | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
34.3 | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
65 | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
Theratechnologies
THTX
|
279 | - | - | $ 83.9 M |  Canada |
 |
Exelixis
EXEL
|
148 | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Gilead Sciences
GILD
|
45.3 | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
55 | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
Insmed Incorporated
INSM
|
227 | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
135 | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
1.88 K | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
1.76 K | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
Longeveron
LGVN
|
241 | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
4.83 K | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mesoblast Limited
MESO
|
1.25 K | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Adaptimmune Therapeutics plc
ADAP
|
43.9 K | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
547 | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
85.8 | $ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
108 | $ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
Merck & Co.
MRK
|
94.5 | $ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
52.8 | - | - | $ 2.02 B | USA |
 |
Curis
CRIS
|
3.24 K | $ 0.88 | 3.67 % | $ 11.6 M | USA |